Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec

Revenues up 37% as TECFIDERA sales soar

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen Idec
 
3Q Revenues: $2.5 billion (+37%)
 
3Q Earnings: $857 million (+76%)
 
YTD Revenues: $7.1 billion (+42%)
 
YTD Earnings: $2.1 million (+47%)
 
Comments: TECFIDERA revenues were $787 million in the quarter, up from $286.4 million in 3Q13, and consisting of $638 million in U.S. sales and $149 million outside the U.S. TYSABRI revenues were $501 million, up 25%. U.S. sales were $275 million and $226 million outside the U.S. Interferon revenues, including AVONEX and PLEGRIDY, were $745 million, consisting of $482 million in U.S. sales and $263 million in sales outside the U.S. Net revenues for the unconsolidated joint business arrangement for RITUXAN and GAZYVA were $291 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters